DNA Repair in Cancer Therapy

Mark R. Kelley, PhD is currently the Betty and Earl Herr Chair in Pediatric Oncology Research, Associate Director for the Herman B Wells Center for Pediatric Research, and the Associate Director of Basic Science Research at the IU Simon Cancer Center. Dr. Kelley’s laboratory studies DNA base excision repair in normal and tumor cells, including the study of DNA repair genes in cognitive dysfunction and peripheral neuropathy. He holds 10 patents related to the use of DNA repair targets for cancer therapy and serves on the consulting and scientific boards of several companies. Thus far Dr. Kelley’s research resulted in over 160 articles published in peer reviewed journals along with numerous reviews and book chapters. Dr. Fishel is a DNA repair expert who is highly published and is at the forefront in the development of new tumor models focusing on DNA repair pathways in cancer.

1. Overview of Current Targets and Clinical Trials: Bench to Clinic2. MGMT a Critical DNA Repair Gene Target for Chemotherapy Resistance3. Blockade of Base Excision Repair: Inhibition of Small Lesions Results in Big Consequences to Cancer Cells4. PARP Inhibitors - Scientific Rationale and Clinical Development for Cancer5. Inhibiting Selective DNA Polymerases for Therapeutic Intervention6. Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications7. Homologous Recombination and ATM/ATR Targets8. DNA Double Strand Break Repair by Nonhomologous End Joining and its Clinical Relevance9. Mismatch repair10. DNA Repair Signaling Targets11. Personalized Cancer Medicine: DNA Repair Alterations is a Promising Predictive Marker in Cancer12. The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies13. Radiation DNA damage and use in cancer/therapeutics/dna repair14. Fanconi Anemia- cross-link repair15. Translesion DNA polymerases16. BRCA1-BRCA2 pathway for HR and synthetic lethality17. Synthetic lethality18. Mechanisms of Resistance to Clinical PARP Inhibitors